Pharmacology of antiepileptic drugs

Epilepsy in Children, 2E

Volumn , Issue , 2004, Pages 358-383

  Fisher, Andrew ^a   Patsalos, Philip N ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33645862687     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (215)

1. Cavell B. Gastric emptying in preterm infants. Acta Paediatrica Scandinavica 1979; 68: 725-730.
2. Jalling B. Plasma and CSF concentrations of phenobarbitone in infants given single doses. Developmental Medicine and Child Neurology 1976; 16: 781-793.
3. Benet LZ, Izumi T, Zhang Y, et al. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. Journal of Control Release 1999; 62: 25-31.
4. Knudsen FU. Plasma diazepam in infants after rectal administration in solution and by suppository. Acta Paediatrica Scandinavica 1977; 66: 563-567.
5. Wilder BJ, Campbell K, Ramsey RE, et al. Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery. Archives of Neurology 1996; 53: 764-768.
6. Bell DM, Richards G, Dhillon S, et al. A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. Epilepsy Research 1991; 10: 183-190.
7. Wroblewski BA, Joseph AB. The use of intramuscular midazolam for acute seizure cessation or behavioural emergencies in patients with traumatic brain injury. Clinical Neuropharmacology 1992; 15: 44-49.
8. De Boer AG, De Leede LG, Breimer DD. Drug absorption by sublingual and rectal routes. British Journal of Anaesthesia 1984; 56: 69-82.
9. Scott RC, Besag FMC, Boyd SG, Berry D, Neville BGR. Buccal absorption of midazolam: pharmacokinetics and EEG pharmacodynamics. Epilepsia 1998; 39: 290-294.
10. Scott RC, Besag FMC, Neville BGR. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet 1999; 353: 623-626.
11. Cornford EM, Partridge WM, Braun LD, et al. Increased bloodbrain barrier transport of protein bound anticonvulsant drugs in the newborn. Journal of Cerebral Blood Flow and Metabolism 1983; 3: 280-286.
12. Painter MJ, Pippenger C, MacDonald H, et al. Phenobarbitone and diphenylhydantoin levels in neonates with seizures. Journal of Pediatrics 1978; 92: 315-319.
13. Patsalos PN, Froscher W, Pisani F, van Rijn CN. The importance of drug interactions in epilepsy therapy. Epilepsia 2002; 43: 365-385.
14. Loebstein R, Koren G. Clinical pharmacology and therapeutic drug monitoring in neonates and children. Pediatric Review 1998; 19: 423-428.
15. Johannessen SI, Bettino D, Berry DJ, et al. Therapeutic drug monitoring of the new antiepileptic drugs. Therapeutic Drug Monitoring 2003; 25(3): 347-363.
16. Callaghan N, O’Callaghan, Duggen B, Feely M. Carbamazepine as a single drug in the treatment of epilepsy. Journal of Neurology, Neurosurgery and Psychiatry 1978; 41: 907-912.
17. Cereghino JJ, Brock JT, van Meter JC, et al. Carbamazepine for epilepsy: a controlled prospective evaluation. Neurology 1974; 24: 401-410.
18. Bruni J, Wilder BJ, Willmore L J, Perchalski RJ, Villareal HJ. Steady-state kinetics of valproic acid in epileptic patients. Clinical Pharmacology and Therapeutics 1978; 24: 324-332.
19. Gannaway DJ, Mawer GE. Serum phenytoin concentration and clinical response in patients with epilepsy. British Journal of Clinical Pharmacology 1981; 2: 833-839.
20. Woo E, Chan YM, Yu YL, Chan YW, Huang CY. If a well stabilized epileptic patient has a subtherapeutic antiepileptic drug level, should the dose be increased? A randomized prospective study. Epilepsia 1988; 29: 129-139.
21. Callaghan N, Kenny RA, O’Neill B, Crowley M, Goggin TA. Prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry 1985; 48: 639-644.
22. Schmidt D, Einicke I, Haenel F. The influence of seizure type on the efficacy of plasma concentration of phenytoin, phenobarbitone and carbamazepine. Archives of Neurology 1986; 43: 263-265.
23. Liu H, Delgado MR. Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. Clinical Pharmacokinetics 1999; 36: 453-470.
24. Drobitch RK, Svensson CK. Therapeutic drug monitoring in saliva: an update. Clinical Pharmacokinetics 1992; 23: 365-379.
25. Gorodischer R, Burtin P, Verjee Z, Hwang P, Koren G. Is saliva suitable for therapeutic monitoring of anticonvulsants in children: an evaluation in the routine clinical setting. Therapeutic Drug Monitoring 1997; 19: 637-642.
26. Luoma PV, Heikkinen JE, Ylostalo PR. Phenobarbitone pharmacokinetics and saliva and serum concentrations in pregnancy. Therapeutic Drug Monitoring 1982; 4: 65-68.
27. Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbitone. Annals of Neurology 1989; 25: 213-220.
28. Macdonald RL, McLean MJ. Anticonvulsant drugs: mechanisms of action. Advances in Neurology 1986; 44: 713-736.
29. Johansen J, Taft WC, Yang J, Kleinhaus AL, DeLorenzo RJ. Inhibition of Ca2_ conductance in identified leech neurons by benzodiazepines. Proceedings of the National Academy of Sciences of the USA 1985; 82: 3935-3939.
30. Walker MC, Tong X, Brown S, Shorvon SD, Patsalos PN. Comparison of single- and repeated-dose pharmacokinetics of diazepam. Epilepsia 1998; 39: 283-289.
31. Dhillon S, Richens A. Valproic acid and diazepam interaction in vivo. British Journal of Clinical Pharmacology 1982; 13: 553-560.
32. Dreiffus FE, Penry JK, Rose SW, et al. Serum clonazepam concentrations in children with absence seizures. Neurology 1975; 25: 255-259.
33. Naito H, Wachi M, Nishida M. Clinical effects and plasma concentrations of long-term clonazepam in monotherapy in previously untreated epileptics. Acta Neurologica Scandinavica 1987; 76: 58-63.
34. Courtney KR, Etter EF. Modulated anticonvulsant block of sodium channels in nerve and muscle. European Journal of Pharmacology 1983; 88: 1-9.
35. Kuo CC, Chen RS, Lu L, Chen RC. Carbamazepine inhibition of neuronal Na_ currents: quantitative distinction from phenytoin and possible therapeutic implications. Molecular Pharmacology 1997; 51: 1077-1083.
36. Ambrósio AF, Silva AP, Malva JO, Soares-da-Silva P, Carvalho CM. Carbamazepine inhibits L-type Ca2_ channels in cultured rat hippocampal neurons stimulated with glutamate receptor antagonists. Neuropharmacology 1999; 38: 1349-1359.
37. Ambrósio AF, Silva AP, Malva JO, Soares-da-Silva P, Carvalho CM. Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. Biochemical Pharmacology 2001; 406: 191-201.
38. Dailey JW, Reith ME, Yan QS, Li MY, Jobe PC. Anticonvulsant doses of carbamazepine increase hippocampal extracellular serotonin in genetically epilepsy-prone rats: dose response relationships. Neuroscience Letters 1997; 227: 13-16.
39. Ichikawa J, Meltzer HY. Valproate and carbamazepine: increase prefrontal dopamine release by 5 HT1A receptor activiation. European Journal of Pharmacology 1999; 380: R1-3.
40. Skerritt JH, Davies LP, Johnston GA. Interactions of the anticonvulsant carbamazepine with adenosine receptors 1. Neurochemical studies. Epilepsia 1983; 24: 634-642.
41. Skerritt JH, Johnston GA, Chow SC. Interactions of the anticonvulsant carbamazepine with adenosine receptors 2. Pharmacological studies. Epilepsia 1983; 24: 643-650.
42. Bano G, Raina RK, Sharma DB. Pharmacokinetics of carbamazepine in protein energy malnutrition. Pharmacology 1986; 32: 232-236.
43. Cornaggia C, Gianetti S, Battino D, et al. Comparative pharmacokinetic study of chewable and conventional carbamazepine in children. Epilepsia 1993; 34: 158-160.
44. Miles MV, Lawless ST, Tennison MB, et al. Rapid loading of critical ill patients with carbamazepine suspension. Pediatrics 1990; 86: 263-266.
45. Eeg-Olofsson O, Nilsson HL, Tonnby B, et al. Diurnal variation of carbamazepine and carbamazepine 10, 11-epoxide in plasma and saliva in children with epilepsy: a comparison between conventional and slow-release formulations. Journal of Child Neurology 1990; 5: 159-165.
46. Patsalos PN. Phenobarbitone to gabapentin: a guide to 82 years of anti-epileptic drug pharmacokinetic interactions. Seizure 1994; 3: 163-170.
47. Patsalos PN, Duncan JS. Antiepileptic drugs. A review of clinically significant interactions. Drug Safety 1993; 9: 156-184.
48. Couet W, Istin B, Ingrand I, Girault J, Fourtillan JB. Effect of ponsinomycin on single-dose kinetics and metabolism of carbamazepine. Therapeutic Drug Monitoring 1990; 12: 144-149.
49. Chadwick D, Shaw MD, Foy P, Rawlins MD, Turnbull DM. Serum anticonvulsant concentrations and the risk of drug induced skin eruptions. Journal of Neurology Neurosurgery and Psychiatry 1984; 47: 642-644.
50. Seetharam MN, Pellock JM. Risk-benefit assessment of carbamazepine in children. Drug Safety 1991; 6: 148-158.
51. Kenneback G, Bergfeldt L, Vallin H, Tomson T, Eldhag O. Electrophysiologic effects and clinical hazards of carbamazepine treatment for neurologic disorders in patients with abnormalities of the cardiac conduction system. American Heart Journal 1991; 121: 1421-1429.
52. Perucca E, Garratt A, Hebdige S, Richens A. Water intoxication in epileptic patients receiving carbamazepine. Journal of Neurology, Neurosurgery and Psychiatry 1978; 41; 713-718.
53. Coulter DA, Huguenard JR, Prince DA. Characterization of ethosuximide reduction of low threshold calcium current in thalamic neurons. Annals of Neurology 1989; 25: 582-593.
54. Kostyuk PG, Molokanova EA, Pronchuk NF, Savchenko AN, Verkhratsky AN. Different action of ethosuximide on low- and high-threshold calcium currents in rat sensory neurons. Neuroscience 1992; 51: 755-758.
55. Pisani F, Narbone MC, Trunfio C, et al. Valproic acidethosuximide interaction: a pharmacokinetic study. Epilepsia 1984; 25: 229-233.
56. Macdonald RL, Rogers CJ, Twyman RE. Barbiturate regulation of kinetic properties of the GABAA receptor channel of mice spinal neurones in culture. Journal of Physiology 1989; 417: 483-500.
57. Heyer EJ, Macdonald RL. Barbiturate reduction of calciumdependent action potentials: correlation with anesthetic action. Brain Research 1982; 236: 157-171.
58. Taburet AM, Chamouard C, Aymard P, et al. Phenobarbitone protein binding in neonates. Developmental Pharmacology and Therapeutics 1982; 4(Suppl. 1): 129-134.
59. Aymard P, Taburet AM, Bauden JJ, et al. Kinetics and metabolism of phenobarbitone in the neonate. In: Johannesen SI, Morselli PL, Pippenger CE, et al. (eds) Antiepileptic Therapy: Advances in Drug Monitoring. New York: Raven Press, 1980; 1-8.
60. Yukawa E, Higuchi S, Aoyama T. The effect of concurrent administration of sodium valproate on serum concentrations of primidone and its metabolite phenobarbitone. Journal of Clinical Pharmacy and Therapeutics 1989; 14: 387-392.
61. Calandre EP, Dominguez-Granados R, Gomez-Rubio M, Molina-Font JA. Cognitive effects of long-term treatment with phenobarbitone and valproic acid in school children. Acta Neurologica Scandinavica 1990; 81: 504-506.
62. Burd L, Kerbeshian J, Fisher W. Does the use of phenobarbitone as an anticonvulsant permanently exacerbate hyperactivity? Canadian Journal of Psychiatry 1987; 32: 10-13.
63. Tunnicliff G. Basis of the antiseizure action of phenytoin. General Pharmacology 1996; 27: 1091-1097.
64. Schwarz JR, Grigat G. Phenytoin and carbamazepine: potentialand frequency-dependent block of Na currents in mammalian myelinated nerve fibers. Epilepsia 1989; 30: 286-294.
65. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1995; 36(Suppl. 2): S2-12.
66. + current. Journal of Pharmacology and Experimental Therapeutics 1998;1 284: 228-237.
67. Rivet M, Bois P, Cognard C, Raymond G. Phenytoin preferentially inhibits L-type calcium currents in whole-cell patch-clamped cardiac and skeletal muscle cells. Cell Calcium 1990; 11: 581-588.
68. Schumacher TB, Beck H, Steinhauser C, Schramm J, Elger CE. Effects of phenytoin, carbamazepine and gabapentin on calcium channels in hippocampal granule cells from patients with temporal lobe epilepsy. Epilepsia 1998; 39: 355-363.
69. Ferrendelli JA. Pharmacology of antiepileptic drugs. Epilepsia 1987; 28(Suppl. 3): S14-16.
70. DeLorenzo RJ. Calmodulin systems in neuronal excitability: a molecular approach to epilepsy. Annals of Neurology 1984; 16(Suppl. 1): S104-114.
71. Rane A, Lunde KM, Jalling B, et al. Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants. Journal of Pediatrics 1971; 78: 877-882.
72. Kauffman RE, Habersang R, Lansky L. Kinetics of primidone metabolism and excretion in children. Clinical Pharmacology and Therapeutics 1977; 22: 200-205.
73. Powell C, Painter M, Pippenger CE. Primidone therapy in refractory neonatal seizures. Journal of Pediatrics 1984; 105: 651-654.
74. Battino D, Avanzini G, Bossi L, et al. Plasma levels of primidone and its metabolite phenobarbitone: effect of age and associated treatment. Therapeutic Drug Monitoring 1983; 5: 73-79.
75. McLean MJ, Macdonald RL. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. Journal of Pharmacology and Experimental Therapeutics 1986; 237: 1001-1011.
76. Albus H, Williamson R. Electrophysiologic analysis of the actions of valproate on pyramidal neurons in the rat hippocampal slice. Epilepsia 1998; 39: 124-139.
77. +] in the hippocampal slice. Brain Research 1986; 386: 1-11.
78. Löscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Progress in Neurobiology 1999; 58: 31-59.
79. Phillips NI, Fowler L J. The effects of sodium valproate on gamma-aminobutyrate metabolism and behaviour in naive and ethanolamine-O-sulphate pretreated rats and mice. Biochemical Pharmacology 1982; 31: 2257-2261.
80. Rowley HL, Marsden CA, Martin KF. Differential effects of phenytoin and sodium valproate on seizure-induced changes in gamma-aminobutyric acid and glutamate release in vivo. European Journal of Pharmacology 1995; 294: 541-546.
81. Sills GJ, Leach JP, Butler E, et al. Antiepileptic drug action in primary cultures of rat cortical astrocytes. Epilepsia 1996; 37(Suppl. 4): S116.
82. Cramer JA, Mattson RH, Bennett DM, Swick CT. Variable free and total valproic acid concentrations in sole- and multi-drug therapy. Therapeutic Drug Monitoring 1986; 8: 411-415.
83. Riva R, Albani F, Franzoni E, et al. Valproic acid free fraction in epileptic children under chronic monotherapy. Therapeutic Drug Monitoring 1983; 5: 197-200.
84. Tartara CA, Galimberti CA, Manni R, et al. Differential effects of valproic acid and enzyme-inducing antiepileptic drugs on nimodipine pharmacokinetics in epileptic patients. British Journal of Clinical Pharmacology 1991; 32: 335-340.
85. Wagner ML, Graves NM, Leppik IE, et al. The effect of felbamate on valproic acid disposition. Clinical Pharmacology and Therapeutics 1994; 56: 494-502.
86. Dreifuss FE. Fatal liver failure in children on valproate. Lancet 1987; 1(8523): 47-48.
87. Thom H, Carter PE, Cole GF, Stevenson KL. Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs. Developmental Medicine and Child Neurology 1991; 33: 795-802.
88. Wallace SJ. A comparative review of the adverse effects of anticonvulsants in children with epilepsy. Drug Safety 1996; 15: 378-393.
89. Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Safety 2001; 24: 969-978.
90. Taylor LA, McQuade RD, Tice MA. Felbamate, a novel antiepileptic drug, reverses N-methyl-D-aspartate/glycinestimulated increases in intracellular Ca2_ concentration. European Journal of Pharmacology 1995; 289: 229-233.
91. Pisani A, Stefani A, Siniscalchi A, et al. Electrophysiological actions of felbamate on rat striatal neurones. British Journal of Pharmacology 1995; 16: 2053-2061.
92. Pugliese AM, Corradetti R. Effects of the antiepileptic drug felbamate on long-term potentiation in the CA1 region of the rat hippocampal slices. Neuroscience Letters 1996; 215: 21-24.
93. Gordon R, Gels M, Diamantis W, Sofia RD. Interaction of felbamate and diazepam against maximal electroshock seizures and chemoconvulsants in mice. Pharmacology Biochemical Behaviour 1991; 40: 109-113.
94. Rho JM, Donevan SD, Rogawski MA. Mechanism of action of the anticonvulsant felbamate: opposing effects on the N-methyl-D-aspartate and _-aminobutyric acid A receptors. Annals of Neurology 1994; 35: 229-234.
95. Palmer KJ, McTavish D. Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs 1993; 45: 1041-1065.
96. Thompson CD, Gulden PH, Macdonald TL. Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration. Chemical Research and Toxicology 1997; 10: 457-462.
97. Kapetanovic IM, Torchin CD, Thompson CD, et al. Potentially reactive cyclic carbamate metabolite of the antiepileptic drug felbamate produced by human liver tissue in vitro. Drug Metabolism and Disposition 1998; 26: 1089-1095.
98. Wagner ML, Graves NM, Marienau K, et al. Discontinuation of phenytoin and carbamazepine in patients receiving felbamate. Epilepsia 1991; 32: 398-406.
99. Glue P, Sulowicz W, Colucci R, et al. Single-dose pharmacokinetics of felbamate in patients with renal dysfunction. British Journal of Clinical Pharmacology 1997; 44: 91-93.
100. Graves NM, Holmes GB, Fuerst RH, Leppik IE. Effect of felbamate on phenytoin and carbamazepine serum concentrations. Epilepsia 1989; 30: 225-229.
101. Kelley MT, Walson PD, Cox S, Dusci L J. Population pharmacokinetics of felbamate in children. Therapeutic Drug Monitoring 1997; 19: 29-36.
102. Reidenberg P, Glue P, Banfield CR, et al. Effects of felbamate on the pharmacokinetics of phenobarbitone. Clinical Pharmacology and Therapeutics 1995; 58: 279-287.
103. Wagner ML, Graves NM, Leppik IE, et al. The effect of felbamate on valproic acid disposition. Clinical Pharmacology and Therapeutics 1994; 56: 494-502.
104. Contin M, Riva R, Albani F, Baruzzi A. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. Therapeutic Drug Monitoring 1999; 21: 604-608.
105. Thompson CD, Kinter MT, Macdonald TL. Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropionaldehyde and 2-phenylpropenal: putative reactive metabolites of felbamate. Chemical Research and Toxicology 1996; 9: 1225-1229.
106. French J, Smith M, Faught E, Brown L. Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy. Neurology 1999; 52: 1540-1545.
107. Pryor FM, Gidal B, Ramsay RE, DeToledo J, Morgan RO. Fosphenytoin: pharmacokinetics and tolerance of intramuscular loading doses. Epilepsia 2001; 42: 245-250.
108. Suman-Chauhan N, Webdale L, Hill DR, Woodruff GN. Characteristics of 3H gabapentin binding to a novel site in rat brain: homogenate binding studies. European Journal of Pharmacology 1993; 244: 293-301.
109. Brown JP, Boden P, Singh L, Gee NS. Mechanisms of action of gabapentin. Reviews in Contemporary Pharmacotherapy 1996; 7: 203-214.
110. Thurlow RP, Brown JP, Gee NS, Hill DR, Woodruff GN. [3H]-Gabapentin may label a system-L-like neutral amino acid carrier in brain. European Journal of Pharmacology 1993; 247: 341-345.
111. Taylor CP, Vartanian MG, Andruszkiewicz R, Silverman RB. 3-Alkyl GABA and 3-alkylglutamic acid analogues: two new classes of anticonvulsant agents. Epilepsy Research 1992; 11: 103-110.
112. Gotz E, Feuerstein TJ, Meyer DK. Effects of gabapentin on release of _-aminobutyric acid from slices of rat neostriatum. Drug Research 1993; 43: 636-638.
113. Leach JP, Sills GJ, Butler E, et al. Neurochemical actions of gabapentin in mouse brain. Epilepsy Research 1997; 27: 175-180.
114. Petroff OAC, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain _-aminobutyric acid in patients with epilepsy. Annals of Neurology 1996; 39: 95-99.
115. 2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002; 42: 229-236.
116. Besag FMC. Gabapentin use with paediatric patients. Reviews in Contemporary Pharmacotherapy 1996; 7: 233-238.
117. McLean MJ. Gabapentin. Epilepsia 1995; 36(Suppl. 2): S57-86.
118. Wilson EA, Sills GJ, Forrest G, Brodie MJ. High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients. Epilepsy Research 1998; 29: 161-166.
119. Dichter MA, Brodie MJ. New antiepileptic drugs. New England Journal of Medicine 1996; 334: 1583-1590.
120. Patsalos PN. New antiepileptic drugs. Annals of Clinical Biochemistry 1999; 36; 10-19.
121. Frank LM, Enlow T, Holmes GL, et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999; 40: 973-979.
122. Stefani A, Spadoni F, Siniscalchi A, Bernadi G. Voltageactivated calcium channels: targets of antiepileptic drug therapy? Epilepsia 1997; 38: 959-965.
123. Ramsey RE. Advances in the pharmacotherapy of epilepsy. Epilepsia 1993; 34(Suppl. 5): S9-15.
124. + channels in rat hippocampal neurones. British Journal of Pharmacology 1997; 121: 1231-1238.
125. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 1986; 27: 490-497.
126. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry 1999; 60: 79-88.
127. Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure 1998; 7: 163-165.
128. Depot M, Powell JR, Messenheimer JA, Cloutier G, Dalton MJ. Kinetic effects of multiple oral doses of acetominophen on a single oral dose of lamotrigine. Clinical Pharamacology and Therapeutics 1990; 48: 346-355.
129. Ebert U, Thong NQ, Oertal R, Kirch W. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. European Journal of Clinical Pharmacology 2000; 56: 299-304.
130. Warner T, Patsalos PN, Prevett M, Elyas AA, Duncan JS. Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10, 11-epoxide. Epilepsy Research 1992; 11: 147-150.
131. Ferrie CD, Robinson RO, Panayiotopoulos CP. Lamotrigine as add-on drug in typical absence seizures. Acta Neurologica Scandinavica 1995; 91: 200-202.
132. Messenheimer J. Efficacy and safety of lamotrigine in pediatric patients. Journal of Child Neurology 2002; 17(Suppl. 2): S34-42.
133. Besag FM, Berry DJ, Pool F, et al. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998; 39: 183-187.
134. Messenheimer J. Efficacy and safety of lamotrigine in pediatric patients. Journal of Child Neurology 2002; 17: 2S34-42.
135. Bartoli A, Guerrini R, Belmonte A, et al. The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: A prospective study with preliminary assessment of correlations with clinical response. Therapeutic Drug Monitoring 1997; 19: 252-260.
136. Morris RG, Black AB, Harris AL, Batty AB, Sallustio BC. Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. British Journal of Clinical Pharmacology 1998; 46: 547-551.
137. Gower AJ, Noyer M, Verloes R, Gobert J, Wülfert E. ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. European Journal of Pharmacology 1992; 222: 193-203.
138. Klitgaard H, Matagne A, Gobert J, Wülfert E. Evidence for a unique profile of levetiracetam in rodent models of seizure and epilepsy European Journal of Pharmacology 1998; 353: 191-206.
139. Löscher W, Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. European Journal of Pharmacology 1993; 232: 147-158.
140. Löscher W, Hönack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. Journal of Pharmacology and Experimental Therapeutics 1998; 284: 474-479.
141. Noyer M, Gillard M, Matagne A, Henichart JP, Wülfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. European Journal of Pharmacology 1995; 286: 137-146.
142. + currents. Seizure 2001; 10: 279-286.
143. Sills GJ, Leach JP, Kilpatrick WS, et al. Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain. European Journal of Pharmacology 1997; 325: 35-40.
144. Poulain P, Margineanu DG. Levetiracetam opposes the action of GABAA antagonists in hypothalamic neurones. Neuropharmacology 2002; 42: 346-352.
145. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacology and Therapeutics 2000; 85: 77-85.
146. Nicolas JM, Collart P, Gerin B, et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metabolism and Disposition 1999; 27: 250-254.
147. Levy RH, Ragueneau-Majlessi I, Baltes E. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Research 2001; 46: 93-99.
148. Sisodiya SM, Sander JWAS, Patsalos PN. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Research 2002; 48: 217-219.
149. Shorvon SD, Löwenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory epilepsy. Epilepsy Research 2000; 42: 89-95.
150. Kossoff EH, Bergey GK, Freeman JM, Vining EPG. Levetiracetam psychosis in children with epilepsy. Epilepsia 2001; 42: 1611-1613.
151. White HS. Comparative anticonvulsant and mechanistic profile of established and newer antiepileptic drugs. Epilepsia 1999; 40(Suppl. 5): S2-10.
152. Schmutz M, Brugger F, Gentsch C, McLean MJ, Olpe HR. Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia 1994; 35(Suppl. 5): S47-50.
153. Parada A, Soares-da-Silva P. The novel anticonvulsant BIA 2-093 inhibits transmitter release during opening of voltagegated sodium channels: a comparison with carbamazepine and oxcarbazepine. Neurochemistry International 2002; 40: 435-440.
154. Stefani A, Pisani A, De Murtas M, et al. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system II. Modulation of high-voltage-activated calcium currents. Epilepsia 1995; 36: 997-1002.
155. McLean MJ, Schmutz M, Wamil AW, et al. Oxcarbazepine: mechanisms of action. Epilepsia 1994; 35: 5-9.
156. Tecoma ES. Oxcarbazepine. Epilepsia 1999; 40(Suppl. 5): S37-46.
157. Theisohn M, Hamann G. Disposition of the antiepileptic drug oxcarbazepine and its metabolites in healthy volunteers. European Journal of Pharmacology 1982; 22: 545-551.
158. Patsalos PN, Elyas AA, Zakrzewska JM. Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia. European Journal of Pharmacology 1990; 39: 413-415.
159. Dickinson RG, Hooper WD, Dunstan PR, Eadie MJ. First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. European Journal of Pharmacology 1989; 37: 69-74.
160. Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994; 35(Suppl. 3): S10-13.
161. Rouan MC, Lecaillon LB, Godbillion J, et al. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites European Journal of Clinical Pharmacology 1994; 47: 161-167.
162. Hossain M, Sallas W, Gaspparini M, et al. Drug-drug interaction profile of oxcarbazepine in children and adults. Neurology 1999; 52(Suppl. 2): A525.
163. May TW, Rambeck B, Jürgens U. Influence of oxcarbazepine and methosuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Therapeutic Drug Monitoring 1999; 21: 175-181.
164. Fattore C, Cipolla G, Gatti G, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999; 40: 783-787.
165. Rättyä J, Vainionpää L, Knip M, et al. The effects of valproate, carbamazepine and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999; 103: 588-593.
166. Beran RG. Cross-reactive skin eruption with both carbamazepine and oxcarbazepine. Epilepsia 1993; 34: 163-165.
167. Van Amelsvoort T, Bakshi R, Devaux CB, et al. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: A review. Epilepsia 1994; 35: 181-188.
168. Borden LA, Dhar TGM, Smith KE, et al. Tiagabine, SK&F 89976-A, CI-966 and NNC-711 are selective for the cloned GABA transporter GAT-1. European Journal of Pharmacology 1994; 269: 219-224.
169. Ribak CE, Tong WM, Brecha C. GABA plasma membrane transporters, GAT-1 and GAT-3, display different distributions in rat hippocampus. Journal of Comparative Neurology 1996; 367: 595-606.
170. Thompson SM, Gähwiler BH. Effects of the GABA uptake inhibitor tiagabine on inhibitory synaptic potential in rat hippocampal slice cultures. Journal of Neurophysiology 1992; 67: 1698-1701.
171. Nielsen EB, Suzdak PD, Andersen KE, et al. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. European Journal of Pharmacology 1991; 196: 257-266.
172. Suzdak PD, Jansen JA. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995; 36: 612-626.
173. Wang X, Patsalos PN. The pharmacokinetic profile of tiagabine. Reviews in Contemporary Pharmacotherapy 2002; 12: 225-233.
174. Adkins JC, Noble S. Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 1998; 55: 437-460.
175. Lau AH, Gustavson LE, Sperelakis R, et al. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia 1997; 38: 445-451.
176. Gustavson LE, Boellner SW, Granneman GR, et al. A single dose study to define tiagabine pharmacokinetics in paediatric patients with complex partial seizures. Neurology 1997; 48: 1032-1037.
177. So EL, Wolff D, Graves NM, et al. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzymeinducing antiepilepsy drugs. Epilepsy Research 1995; 22: 221-226.
178. Brodie MJ. Tiagabine pharmacology in profile. Epilepsia 1995; 36(Suppl. 6): S7-9.
179. Piccinelli P, Borgatti R, Perucca E, et al. Frontal non-convulsive status epilepticus associated with high-dose tiagabine therapy in a child with familial bilateral perisylvian polymicrogyria. Epilepsia 2000; 41: 1485-1488.
180. Patsalos PN, Elyas AA, Ratnaraj N, Iley J. Concentrationdependent displacement of tiagabine by valproic acid. Epilepsia 2002; 43(Suppl. 8): 143.
181. Buttery PC, Sisodiya SM. The safety, tolerability and adverse events profile of tiagabine. Reviews in Contemporary Pharmacotherapy 2002; 12: 251-264.
182. Schmidt D, Gram L, Brodie MJ, et al. Tiagabine in the treatment of epilepsy - a clinical review with a guide for the prescribing physician. Epilepsy Research 2000; 41: 245-251.
183. DeLorenzo RJ, Sombati S, Coulter DA. Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons. Epilepsia 2000; 41(Suppl. 1): S40-44.
184. +currents in CA1 pyramidal neurons in vitro. Epilepsia 1998; 39(Suppl. 2): 44.
185. White HS, Brown SD, Skeen GA, Wolf HH, Twymann RE. The anticonvulsant topiramate displays a unique ability to potentiate GABA-evoked chloride currents. Epilepsia 1995; 36(Suppl. 3): S39-40.
186. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Research 1997; 28: 167-179.
187. Severt L, Coulter DA, Sombati S, DeLorenzo RJ. Topiramate selectively blocks kainate currents in cultured hippocampal neurons. Epilepsia 1995; 36(Suppl. 4): 38.
188. Petroff OAC, Hyder F, Mattson RH, Rothman DL. Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. Neurology 1999; 52: 473-478.
189. Nayak RK, Gisclon LG, Curtin CA, Benet LZ. Estimation of the absolute bioavailability of topiramate in humans without intravenous data. Journal of Clinical Pharmacology 1994; 34: 1029.
190. Patsalos PN. The pharmacokinetic profile of topiramate. Reviews in Contemporary Pharmacotherapy 1999; 10: 155-162.
191. Doose DR, Walker SA, Gisclon LG, Nayak RK. Single dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. Journal of Clinical Pharmacology 1996; 36: 884-891.
192. Doose DR, Scott VV, Margul BL, Marriot TB, Nayak RK. Multiple-dose pharmacokinetics of topiramate in healthy male subjects. Epilepsia 1988; 29(Suppl. 2): 662.
193. Easterling DE, Zakszewski T, Moyer MD, et al. Plasma pharmacokinetics of topiramate, a new anticonvulsant in humans. Epilepsia 1988; 29: 662.
194. Sachdeo RC, Sachdeo SK, Walker SA, et al. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996; 37: 774-780.
195. May TW, Rambeck B, Jurgens U. Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. Therapeutic Drug Monitoring 2002; 24: 366-374.
196. Contin M, Riva R, Albani F, Avoni P, Baruzzi A. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Therapeutic Drug Monitoring 2002; 24: 332-337.
197. Rosenfeld WE, Liao S, Kramer LD, et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1997; 38: 324-333.
198. Yerby M. Topiramate displacement of valproic acid binding sites. Epilepsia 1997; 38(Suppl. 3): 67-68.
199. Liao S, Palmer M. Digoxin and topiramate drug interaction in male volunteers. Pharmaceutical Research 1993; 10: S405.
200. Lippert B, Metcalf B, Jung MJ, Casara P. 4-Amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric acid transferase in mammalian brain. European Journal of Biochemistry 1977; 74: 441-445.
201. Patsalos PN, Duncan JS. The pharmacology and pharmacokinetics of vigabatrin. Reviews in Contemporary Pharmacotherapy 1995; 6: 447-456.
202. Sheth RD, Buckley D, Penney S, Hobbs GR. Vigabatrin in childhood epilepsy: comparable efficacy for generalized and partial seizures. Clinical Neuropharmacology 1996; 19: 297-304.
203. Kälviänen R, Nousiainen I, Mäntyjärvi M, et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999; 53: 922-932.
204. Lawden MC, Eke T, Degg C, Harding GFA, Wild JM. Visual field defects associated with vigabatrin therapy. Journal of Neurology, Neurosurgery and Psychiatry 1999; 67: 716-722.
205. Wild JM, Martinez C, Reinshagen G, Harding GFA. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999; 40: 1784-1794.
206. Cross-Tsur V, Banin E, Shahar E, Shalev RS, Lahat E. Visual impairment in children with epilepsy treated with vigabatrin. Annals of Neurology 2000; 48: 60-64.
207. Juhász C, Muzik O, Chugani DC, et al. Prolonged vigabatrin treatment modifies developmental changes of GABAAreceptor binding in young children with epilepsy. Epilepsia 2002; 42: 1310-1326.
208. Peters DH, Sorkin EM. Zonisamide. A review of its pharmacodynamic properties and therapeutic potential in epilepsy. Drugs 1993; 45; 760-787.
209. Rock DM, Macdonald RL, Taylor CP. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912) a novel anticonvulsant. Epilepsy Research 1989; 3: 138-143.
210. Suzuki S, Kawakami K, Nishimura S, et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Research 1992; 12: 21-27.
211. Leppik IE. Zonisamide. Epilepsia 1999; 40(Suppl. 5): S23-29.
212. Shinoda M, Akita M, Hasegawa M, Hasegawa T, Nabeshima T. The necessity of adjusting the dosage of zonisamide when coadministered with other anti-epileptic drugs. Biological Pharmacy Bulletin 1996; 19: 1090-1092.
213. Berent S, Sackellares JC, Giordani B, et al. Zonisamide (CI-912) and cognition: results from preliminary study. Epilepsia 1987; 28: 61-67.
214. Kawada K, Itoh S, Kusaka T, Isobe K, Ishii M. Pharmacokinetics of zonisamide in perinatal period. Brain and Development 2002; 24: 95-97.
215. Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Therapeutic Drug Monitoring 1998; 20: 593-597.